An innovative new wound care technology will now allow veterinarians in the Benelux countries to protect wounds from bacterial infections and help heal animal wounds faster. Amferia announced a distribution partnership with Grovet BV —a major player serving the animal health market in European countries including Netherlands, Belgium, and Luxemburg.
The joint efforts will aim to make products available as soon as the spring of 2026.
The partnership with Grovet will bring a groundbreaking treatment to animal patients in the Benelux region. Extensive research across Europe demonstrates that Amferia’s dressing helps heal wounds significantly faster than currently available dressings.
But Amferia’s greatest promise might lie in its proven ability to counter the rising threat of antibiotic-resistant bacteria. Because Amferia kills bacteria by drawing them close and physically puncturing their cell membranes, even bacterial strains that have developed a resistance to medical antibiotics cannot effectively resist this interaction.
This distribution agreement follows a milestone year in which Amferia introduced Europe’s first veterinary wound dressing using antimicrobial peptides, launched in collaboration with leading animal-health partners, and advanced efforts to achieve regulatory approval in the U.S. for human wound care.
Fueling Growth Across Veterinary Wound Care
According to Amferia Sales and Marketing Director and co-founder Saba Atefyekta, the new partnership will help Grovet advance its animal wound care offerings, as well as expand Amferia’s animal-health footprint in Europe, where its products are already available in Scandinavia, Germany, Spain and Switzerland.
“Grovet’s market leadership in animal health will spearhead Amferia’s vision of addressing antibiotic-resistant wound infections. This partnership brings our innovation together with a leading partner in a market in need of new solutions. Veterinarians across Europe have shown strong interest in our innovation. They immediately recognize the potential for our new antimicrobial material for wound and infection management,” Atefyekta said.
“We are very excited about Amferia’s innovative technology for wound care in animals and we clearly see its potential to contribute to the battle against antibiotic-resistance. We are looking forward to launch AMP Wound Dressing in the Benelux very soon,” said Chris Dujardin, Head of Business Development at Grovet.
